Lilly's internal probe into Branchburg, New Jersey, plant found company didn't mislead FDA, but DOJ investigation remains: report

When Eli Lilly last month revealed that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New Jersey, the drugmaker's own independent investigation had already wrapped up and concluded the company didn't make false statements to the FDA, Reuters reports.